139 related articles for article (PubMed ID: 27471639)
21. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
Cornel AM; Dunnebach E; Hofman DA; Das S; Sengupta S; van den Ham F; Wienke J; Strijker JGM; van den Beemt DAMH; Essing AHW; Koopmans B; Engels SAG; Lo Presti V; Szanto CS; George RE; Molenaar JJ; van Heesch S; Dierselhuis MP; Nierkens S
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521927
[TBL] [Abstract][Full Text] [Related]
22. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW; Huang M; Dalton GN; Alexe G; Schaefer DA; Geraghty AC; Robichaud AL; Conway AS; Khalid D; Mader MM; Belk JA; Ross KN; Sheffer M; Linde MH; Ly N; Yao W; Rotiroti MC; Smith BAH; Wernig M; Bertozzi CR; Monje M; Mitsiades CS; Majeti R; Satpathy AT; Stegmaier K; Majzner RG
Nat Cancer; 2022 Aug; 3(8):976-993. PubMed ID: 35817829
[TBL] [Abstract][Full Text] [Related]
23. Advancing therapy for neuroblastoma.
Qiu B; Matthay KK
Nat Rev Clin Oncol; 2022 Aug; 19(8):515-533. PubMed ID: 35614230
[TBL] [Abstract][Full Text] [Related]
24. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.
Adeshakin AO; Adeshakin FO; Yan D; Wan X
Front Immunol; 2022; 13():781660. PubMed ID: 35140716
[TBL] [Abstract][Full Text] [Related]
25. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
[TBL] [Abstract][Full Text] [Related]
26. Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.
Ciaccio R; De Rosa P; Aloisi S; Viggiano M; Cimadom L; Zadran SK; Perini G; Milazzo G
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884690
[TBL] [Abstract][Full Text] [Related]
27. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Villablanca JG; Vo KT; Pinto N; Mosse YP; Maris JM; Shusterman S; Cohn SL; Goldsmith KC; Weiss B; Yanik GA; Twist CJ; Irwin MS; Haas-Kogan DA; Park JR; Marachelian A; Matthay KK
J Clin Oncol; 2021 Nov; 39(31):3506-3514. PubMed ID: 34270348
[TBL] [Abstract][Full Text] [Related]
28. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.
Cui Y; Cai J; Wang W; Wang S
Front Immunol; 2021; 12():690207. PubMed ID: 34149732
[TBL] [Abstract][Full Text] [Related]
29. Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment.
Frosch J; Leontari I; Anderson J
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917501
[TBL] [Abstract][Full Text] [Related]
30. Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model.
van den Bijgaart RJE; Kroesen M; Brok IC; Reijnen D; Wassink M; Boon L; Hoogerbrugge PM; Adema GJ
Oncoimmunology; 2020 Sep; 9(1):1817653. PubMed ID: 33457098
[TBL] [Abstract][Full Text] [Related]
31. Reduction of CD11b
Siebert N; Zumpe M; von Lojewski L; Troschke-Meurer S; Marx M; Lode HN
Oncoimmunology; 2020 Oct; 9(1):1836768. PubMed ID: 33150046
[TBL] [Abstract][Full Text] [Related]
32. Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts.
Wrobel JK; Najafi S; Ayhan S; Gatzweiler C; Krunic D; Ridinger J; Milde T; Westermann F; Peterziel H; Meder B; Distel M; Witt O; Oehme I
Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33121173
[TBL] [Abstract][Full Text] [Related]
33. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.
Liu KX; Joshi S
Front Immunol; 2020; 11():1947. PubMed ID: 32983125
[TBL] [Abstract][Full Text] [Related]
34. Gangliosides and Neuroblastomas.
Schengrund CL
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32726962
[TBL] [Abstract][Full Text] [Related]
35. Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers.
Kailayangiri S; Altvater B; Wiebel M; Jamitzky S; Rossig C
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32357417
[TBL] [Abstract][Full Text] [Related]
36. Targets and Antibody Formats for Immunotherapy of Neuroblastoma.
Park JA; Cheung NV
J Clin Oncol; 2020 Jun; 38(16):1836-1848. PubMed ID: 32167865
[TBL] [Abstract][Full Text] [Related]
37. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
Voeller J; Sondel PM
J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
[TBL] [Abstract][Full Text] [Related]
38. EZH2 Inhibition in Ewing Sarcoma Upregulates G
Kailayangiri S; Altvater B; Lesch S; Balbach S; Göttlich C; Kühnemundt J; Mikesch JH; Schelhaas S; Jamitzky S; Meltzer J; Farwick N; Greune L; Fluegge M; Kerl K; Lode HN; Siebert N; Müller I; Walles H; Hartmann W; Rossig C
Mol Ther; 2019 May; 27(5):933-946. PubMed ID: 30879952
[TBL] [Abstract][Full Text] [Related]
39. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
[TBL] [Abstract][Full Text] [Related]
40. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.
García-Martínez E; Smith M; Buqué A; Aranda F; de la Peña FA; Ivars A; Cánovas MS; Conesa MAV; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2018; 7(6):e1433982. PubMed ID: 29872569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
